| Dr Charles E Graham, MD | |
|
3435 W Craig Rd Ste A, North Las Vegas, NV 89032-5116 | |
| (702) 733-6673 | |
| Not Available |
| Full Name | Dr Charles E Graham |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 3435 W Craig Rd Ste A, North Las Vegas, Nevada |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134270390 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 6794 (Nevada) | Primary |
| 207W00000X | Ophthalmology | 21459 (Arizona) | Secondary |
| 207W00000X | Ophthalmology | 22808 (Kansas) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles E Graham, MD Po Box 34405, 3435 W. Craig Rd. Suite A, Las Vegas, NV 89133-4405 Ph: (702) 733-6673 | Dr Charles E Graham, MD 3435 W Craig Rd Ste A, North Las Vegas, NV 89032-5116 Ph: (702) 733-6673 |
News Archive
A study conducted by a team of researchers at the New York University has found an unexpected source for the development of the brain. According to the research, which was published in the journal Science, a group of non-neuronal cells called glia, which were previously considered as passive support cells, are important for the development of nerve-cells present in the brain.
"Last week in Washington, D.C., a coalition of global leaders and international organizations launched the Child Survival Call to Action in an effort to drive down the risk of preventable child deaths to roughly equivalent levels in all countries by 2035," Victoria Fan, a research fellow at the Center for Global Development (CGD), writes in this post in the center's "Global Health Policy" blog.
BioTime, Inc. today announced a $4 million equity financing by its subsidiary, Embryome Sciences, Inc. Concurrent with the financing, Embryome Sciences will be renamed ReCyte Therapeutics, Inc. and will develop therapeutic products for cardiovascular and blood diseases. The new equity financing is being led by a $2.5 million investment by private investors and a $1.5 million investment from BioTime that valued ReCyte Therapeutics at a post money valuation of $60 million on a fully diluted basis.
Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Pioglitazone Hydrochloride Tablets. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA), which is being manufactured and supplied by Synthon Pharmaceuticals, Inc., and will be available in 15 mg, 30 mg, and 45 mg strengths.
› Verified 8 days ago
Dr. James Daniel Carpenter, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3210 E Lake Mead Blvd, North Las Vegas, NV 89030 Phone: 702-642-7711 Fax: 702-642-8822 | |
Richard J Maw, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2517 E Lake Mead Blvd, North Las Vegas, NV 89030 Phone: 702-642-7711 Fax: 702-642-8822 |